5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.83▲ | 3.77▲ | 3.77▲ | 3.69▲ | 4.03▼ |
MA10 | 3.77▲ | 3.69▲ | 3.69▲ | 3.81▲ | 2.10▲ |
MA20 | 3.66▲ | 3.65▲ | 3.64▲ | 3.85▼ | 1.17▲ |
MA50 | 3.59▲ | 3.83▲ | 3.93▼ | 1.65▲ | 0.78▲ |
MA100 | 3.93▼ | 4.17▼ | 4.09▼ | 0.95▲ | 1.82▲ |
MA200 | 4.18▼ | 3.03▲ | 2.13▲ | 0.65▲ | 9.28▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.035▲ | 0.054▲ | 0.062▲ | -0.158▼ | 0.453▲ |
RSI | 56.563▲ | 54.465▲ | 53.425▲ | 61.720▲ | 76.400▲ |
STOCH | 50.625 | 57.949 | 57.949 | 19.324▼ | 45.223 |
WILL %R | -36.923 | -36.923 | -36.923 | -72.872 | -50.467 |
CCI | 77.437 | 97.736 | 104.493▲ | -42.511 | 83.894 |
Friday, June 27, 2025 04:58 PM
SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced ...
|
Thursday, June 12, 2025 05:00 PM
Health, Inc. Odyssey, a 10% owner of $OGEN, sold 5,000 shares of the company on 06-13-2025 for an estimated $21,349. We received data on the trade from a recent SEC ...
|
Monday, May 26, 2025 05:00 PM
SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company advancing innovative treatments for brain-related ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
30/06/25 | 3.88 | 3.975 | 3.581 | 3.82 | 133,036 |
27/06/25 | 3.54 | 4.19 | 3.31 | 4.05 | 308,500 |
26/06/25 | 3.56 | 3.88 | 3.31 | 3.49 | 190,541 |
25/06/25 | 3.63 | 3.83 | 3.46 | 3.46 | 81,200 |
24/06/25 | 3.56 | 3.7985 | 3.491 | 3.61 | 46,909 |
23/06/25 | 3.62 | 3.66 | 3.41 | 3.56 | 49,300 |
20/06/25 | 3.67 | 3.78 | 3.56 | 3.65 | 36,000 |
18/06/25 | 4.25 | 4.37 | 3.675 | 3.71 | 82,925 |
17/06/25 | 4.85 | 4.85 | 4.28 | 4.37 | 67,477 |
16/06/25 | 4.61 | 4.672 | 4.17 | 4.35 | 46,336 |
|
|
||||
|
|
||||
|
|